Title

Hyperpolarization-activated cyclic nucleotide gated channels: a potential molecular link between epileptic seizures and Aβ generation in Alzheimer's disease

Author(s)

Saito, Yuhki; Inoue, Tsuyoshi; Zhu, Gang; Kimura, Naoki; Okada, Motohiro; Nishimura, Masaki; Kimura, Nobuyuki; Murayama, Shigeo; Kaneko, Sunao; Shigemoto, Ryuichi; Imoto, Keiji; Suzuki, Toshiharu

Citation

Molecular Neurodegeneration, 7, 50
https://doi.org/10.1186/1750-1326-7-50

Issue Date

2012-10-03

Doc URL

http://hdl.handle.net/2115/51384

Rights(URL)

http://creativecommons.org/licenses/by/2.0/

Type

article

File Information

MN7_50.pdf

Hokkaido University Collection of Scholarly and Academic Papers: HUSCAP
Hyperpolarization-activated cyclic nucleotide gated channels: a potential molecular link between epileptic seizures and Aβ generation in Alzheimer’s disease

Yuhki Saito1, Tsuyoshi Inoue2, Gang Zhu3, Naoki Kimura1, Motohiro Okada4, Masaki Nishimura5, Nobuyuki Kimura6, Shigeo Murayama7,8, Sunao Kaneko9, Ryuichi Shigemoto10, Keiji Imoto11 and Toshiharu Suzuki1*

Abstract

Background: One of the best-characterized causative factors of Alzheimer’s disease (AD) is the generation of amyloid-β peptide (Aβ). AD subjects are at high risk of epileptic seizures accompanied by aberrant neuronal excitability, which in itself enhances Aβ generation. However, the molecular linkage between epileptic seizures and Aβ generation in AD remains unclear.

Results: X11 and X11-like (X11L) gene knockout mice suffered from epileptic seizures, along with a malfunction of hyperpolarization-activated cyclic nucleotide gated (HCN) channels. Genetic ablation of HCN1 in mice and HCN1 channel blockage in cultured Neuro2a (N2a) cells enhanced Aβ generation. Interestingly, HCN1 levels dramatically decreased in the temporal lobe of cynomolgus monkeys (Macaca fascicularis) during aging and were significantly diminished in the temporal lobe of sporadic AD patients.

Conclusion: Because HCN1 associates with amyloid-β precursor protein (APP) and X11/X11L in the brain, genetic deficiency of X11/X11L may induce aberrant HCN1 distribution along with epilepsy. Moreover, the reduction in HCN1 levels in aged primates may contribute to augmented Aβ generation. Taken together, HCN1 is proposed to play an important role in the molecular linkage between epileptic seizures and Aβ generation, and in the aggravation of sporadic AD.

Background

Alzheimer’s disease (AD) is characterized by progressive memory impairment, which accompanies aging. Genetic and biochemical studies show that the production of amyloid-β peptide (Aβ) largely contributes to the etiology of AD [1]. Aβ is generated from amyloid-β precursor protein (APP) by β- and γ-cleavage of the latter.

The risk of seizure activity is particularly high in AD patients, with an 87-fold increase in subjects with early-onset dementia compared with an age-matched reference population [2–7]. Factors linking seizure activity to Aβ generation in AD patients remain unclear, although epilepsy is believed to result from abnormal regulation of neuronal excitability, which favors hypersynchrony. In addition, increased neuronal activity enhances Aβ production from APP [8–10].

Hyperpolarization-activated cyclic nucleotide gated HCN channels 1–4 (HCN1–4) conduct inward, depolarizing mixed Na+/K+ currents and thereby control resting membrane potential, dendritic integration, synaptic transmission, and rhythmic activity in cardiac pacemaker cells and spontaneous firing neurons [11]. Dysregulation of these channels and their hyperpolarization-activated (Ih) currents is strongly implicated in various experimental animal models of epilepsy, as well as in human epilepsy patients [12]. Furthermore, HCN2 co-assembles with the X11-like (X11L) protein [13], which is a metabolic regulator of APP processing [14].

X11 proteins (X11s) comprise a family of three evolutionarily conserved molecules (X11/X11α/Mint1, X11L/
X11β/Mint2, and X11L2/X11y/Mint3). These proteins bind to the cytoplasmic region of APP in cultured cells and suppress its metabolism [15,16]. Moreover, the metabolism of overexpressed human APP (hAPP) is suppressed in X11 and X11L transgenic mice, along with the generation of Aβ [17-19]. On the other hand, mutant mice lacking X11L (X11+/+X11L−/− mice) or both X11 and X11L (X11+/+X11L−/− mice) facilitate amyloidogenic metabolism of endogenous murine APP and exogenous hAPP, including Aβ generation [20-22]. Therefore, inactivation of X11/X11L clearly increases the production of Aβ, potentially contributing to the pathology of AD.

Here, we report that i) X11−/−/X11L−/− mice suffer from spontaneous epileptic seizures along with malfunction of HCN channel activity; ii) HCN1 can form a complex with APP and X11 or X11L in the murine brain; iii) HCN1−/− gene knockout mice show enhanced Aβ generation; iv) overexpression of HCN1 in Neuro2a (N2a) cells decreases Aβ generation, whereas blockade of HCN1 channel activity in N2a cells restores the level of Aβ production; v) the level of HCN1 diminishes significantly in the temporal cortex of cynomolgus monkeys (Macaca fascicularis) during aging; and vi) HCN1 levels are significantly reduced in the brains of sporadic AD patients compared with the brains of age-matched healthy subjects. Given the previous reports and our current observations, we hypothesize that X11 and X11L play an important role in the modulation of HCN channel function, the dysregulation of which correlates with epilepsy. We further hypothesize that the impairment of HCN channels, and in particular HCN1, accompanies with the aberrant production of Aβ, which manifests as neurotoxicity. Thus, HCN1 together with X11 and X11L may provide a molecular link between seizure activity and Aβ generation in AD patients.

Results

**Spontaneous epileptic seizures caused by X11 and X11L gene deficiency**

Electrocorticograms were recorded in X11+/+X11L+/+ (wild type), X11+/+X11L−/−, X11−/−X11L+/+, and X11−/−X11L−/− mice. We found that X11−/−X11L−/− mice suffered from spontaneous epileptic seizures at the age of 13 weeks and over (detailed results are provided in Additional file 1: Figure S1 and Additional file 2: Movies S1, Additional file 3: Movies S2 and Additional file 4: Movies S3). Three out of four X11−/−X11L−/− mice showed an abnormal electrocorticogram recording within 48 h, namely, the presence of epileptic discharge, which were never observed in X11+/+X11L+/+, X11+/+X11L−/−, or X11−/−X11L+/+

**Figure 1 Electrocorticogram recording and histological changes associated with epileptic seizures in X11−/−X11L−/− mice.** (A) An electrocorticogram recorded in 13-week-old X11−/−X11L−/− mice (n = 4). Epileptic discharges are underlined. (B) c-Fos (a, b, c) and Egr-1/zif268 (d, e, f) immunoreactivity in the hippocampus of X11−/−X11L−/− (a, d) and X11−/−X11L−/− (b, c, e, f) mice under steady-state conditions (a, b, d, e) and at 90 min after an epileptic episode (c, f). Scale bar, 200 μm.
mice (Figure 1, Additional file 1: Figure S1 and Additional file 4: Movie S3). Subsets of X11−/−/X11L−/− mice went into status epilepticus and died. Seizures are often associated with the augmented expression of immediate-early genes in neurons [23]. We first asked whether such gene activation was observed in X11−/−/X11L−/− mice following epileptic seizures and investigated the involvement of specific brain regions in seizure activity. Brain tissue sections from X11−/−/X11L−/− mice were immunostained for c-Fos, a calcium-dependent immediate-early gene product, and Egr-1/Zif268, an early growth response transcription factor, within 90 min of a seizure event. The brains of these mice showed enhanced expression of both c-Fos and Egr-1/Zif268 in the dentate gyrus (DG) granule cells compared with the brains of X11+/+/X11L+/+ and X11−/−/X11L−/− mice (Figure 1B). However, we cannot rule out a possibility that subclinical discharges without aberrant behavior may

![Figure 2](https://example.com/figure2.png)

**Figure 2** Expression of X11 and X11L in the 13-week-old mouse brain. Representative images of horizontal brain sections from 13-week-old X11+/+X11L+/+ mice were stained for X11 (C, F, I, L) and X11L (B, E, H, K). Immunohistochemistry was performed with anti-X11 polyclonal rabbit IgG followed by donkey anti-mouse IgG conjugated to Alexa Fluor 488, and anti-X11L monoclonal mouse IgG followed by donkey anti-rabbit IgG conjugated to Cy3. Merged images are shown in the left panels (A, D, G, J). Blue signals indicate nuclei counter-stained with DAPI. Scale bars, 300 μm (A–C, G, J), 50 μm (D–L).
cause the enhanced expression of c-Fos and Egr-1/Zif268. Thus, a deficiency in both X11 and X11L may cause abnormal, seizure-associated neuronal activity and subsequent alterations in protein expression in the hippocampal formation.

Reduction of Ih currents in entorhinal cortex (EC) layer II of X11−/−/X11L−/− mice

Spontaneous epileptic seizures were observed in mice when both X11 and X11L genes were deficient (Figure 1A, Additional file 1: Figure S1 and additional movies). Because the DG granule cells of X11−/−/X11L−/− mice showed augmented expression of c-Fos and Egr-1/Zif268 following seizure activity, we next performed a detailed examination of the expression of both proteins in hippocampal neurons in 13-week-old murine brains (Figure 2).

Distinct expression patterns of X11 and X11L were observed in the hippocampus of wild type mice. X11L was expressed mainly in the pyramidal neurons of the CA1–3 region (Figure 2B, E, H), whereas X11 was expressed in other types of interneurons (Figure 2C, F, I). These observations coincide with our previous report of X11s expression in aged wild type mice [21]. Unlike c-Fos and Egr-1/Zif268 in the double mutant mouse, X11 and X11L were not expressed in DG granule cells (Figure 2D–F). However, both X11 and X11L were strongly co-expressed in EC layer II (Figure 2J–L), which projects axons primarily to the granule cells of the DG [24]. Furthermore, both HCN1 and HCN2 are expressed in EC layer II [25]. Given that HCN1−/− mice show enhanced seizure susceptibility and that HCN2−/− mice suffer from absence seizures [26,27], we next focused our investigations on the alteration of Ih currents associated with HCN channels in EC layer II in X11−/−/X11L−/− mice.

Horizontal brain slices that included the EC and the hippocampus were prepared from 12–14-week-old X11−/−/X11L−/−, X11−/−/X11L−/+, X11−/−/X11L+/−, and X11−/−/X11L+/+ mice. EC layer II neurons were then subjected to electrophysiological analysis, and Ih currents from HCN channels were recorded (Figure 3 and Additional file 1: Figure S2). The mice used in the electrophysiological study were seizure-naïve, at least without over behavioral manifestations, and showed comparable levels of HCN1 channels in EC layer II of X11−/−/X11L−/− mice.

The Ih current was dramatically reduced in X11−/−/X11L−/− mice (Figure 3A and C). By contrast, the Ih current was considerably reduced in X11−/−/X11L−/+ mice relative to that in X11−/−/X11L+/− mice (Figure 3B and D); however, no significant alterations were observed for the V1/2 (mean ± SEM, X11−/−/X11L−/+: −81.1±1.1 mV; X11−/−/X11L−/+: −80.3±1.3 mV; X11−/−/X11L−/+: −83.5±1.4 mV; X11−/−/X11L−/+: −81.3±0.9 mV) (Figure 3E) or the series resistance (mean ± SEM, X11−/−/X11L−/+: 8.3±0.2 MΩ; X11−/−/X11L−/+: 8.9±0.5 MΩ; X11−/−/X11L−/+: 9.2±0.4 MΩ; X11−/−/X11L−/+: 8.0±0.2 MΩ) (Figure 3F).

Quantitative analysis (Figure 3G) revealed that the density of the Ih current was also significantly reduced in X11−/−/X11L−/− mice (1.12±0.15 pA/pF, n = 9; p < 0.01) compared with that in X11−/−/X11L−/+ mice (2.18±0.27 pA/pF, n = 10), but did not change significantly in X11−/−/X11L−/+ mice (2.41±0.25 pA/pF, n = 9, p > 0.05) or in X11−/−/X11L−/− mice (2.05±0.29 pA/pF; n = 9, p > 0.05). Thus, genetic ablation of X11 and X11L together had a profound impact on the Ih current in the EC layer II of the double knockout mice. These results correlate with the observation that X11−/−/X11L−/− mice, but not X11−/−/X11L−/+ or X11−/−/X11L−/+ mice, are susceptible to spontaneous epileptic seizures.

In EC layer II, the dominant HCN subtype is HCN1 [28]. We found that HCN1, X11, and X11L were colocalized in EC layer II neurons (Figure 3H) and apparently formed a complex in the brain (Figure 3I–K). The colocalization of these molecules was observed in a region surrounding the neuronal nucleus (Figure 3H), consistent with the location of the Golgi apparatus. Because X11 and X11L are largely localized in the Golgi apparatus and function in the trafficking of membrane proteins [29,30], the deletion of X11 and X11L may disturb intracellular localization of HCN channels (Additional file 1: Figure S4). While the localization of the channel likely affects its function, we cannot rule out the possibility that X11 and X11L directly regulate HCN1 function as well.

Enhanced Aβ generation according to HCN1 dysfunction

The EC is one of the most vulnerable brain regions in AD [31], and it is well-known that synaptic activity such as that mediated by HCN channels can regulate Aβ generation [8–10]. Therefore, we examined whether HCN channel impairment involved in the aberrant production of Aβ. We first quantified the levels of endogenous Aβ40 and Aβ42 in HCN1−/− mouse brains. Aβ40 and Aβ42 were both significantly increased in the cortex of HCN1−/− mice compared with HCN1−/− mice (average ± SEM, Aβ40: n = 5, p = 0.0037; Aβ42: n = 5, p = 0.0055) (Figure 4A). The magnitude of the increase in Aβ40 and Aβ42 was inversely proportional to the level of HCN1 gene expression (Figure 4A, left panel), while APP protein levels were comparable in HCN1−/−, HCN1+/−, and HCN1−/− mice (Figure 4A, right panel).

To confirm whether the increase in Aβ generation in HCN1−/− mice depends on the decrease in HCN channel activity, we used N2a cells that transiently overexpressed FLAG-APP and HCN1 (Figure 4B). Overexpression of HCN1 significantly reduced the generation of Aβ40 and Aβ42 (compare column 2 with column 3 for each Aβ peptide). The Aβ levels were restored by adding ZD7288, a
Figure 3 Reduction of Ih currents in entorhinal cortex layer II neurons of X11+/−/X11L+/− mice. (A, B) Representative electrophysiological recordings of Ih currents from EC layer II neurons in X11+/−/X11L+/− (A) and X11+/−/X11L−/− (B) mice. (C, D) Tail currents of X11+/−/X11L+/− (C) and X11−/−/X11L−/− (D) mice. (E) Quantitative data of the voltage, whereby the current is half-activated (V1/2). Statistical analysis was performed using one-way analysis of variance followed by Tukey’s multiple comparison test (mean ± SEM (mV); five slices from two X11+/−/X11L+/− mice, n = 10; four slices from two X11+/−/X11L−/−, X11+/−/X11L+/−, and X11+/−/X11L−/− mice, n = 9). (F) Quantitative data of series resistance. Statistical analysis was performed as described (mean ± SEM (MΩ); five slices from two X11+/−/X11L+/− mice, n = 10; four slices from two X11+/−/X11L−/−, X11+/−/X11L+/−, and X11+/−/X11L−/− mice, n = 9). (G) Summary of the current density of the tail currents. Statistical analysis was performed as described (mean ± SEM (pA/pF); five slices from two X11+/−/X11L+/− mice, n = 10; four slices from two X11+/−/X11L−/−, X11+/−/X11L+/−, and X11+/−/X11L−/− mice, n = 9; **p < 0.01). (H) Representative images of the HCN1-X11-X11L complex in EC layer II neurons of 13-week-old X11+/−/X11L+/− mice (a, merge; b HCN1 (green); c, X11L (red); d, X11 (blue)). Scale bar, 20 μm. (I−K) Co-immunoprecipitation of HCN1-X11s complexes from the 13-week-old X11+/−/X11L+/− murine cortex. HCN1−/− (I), X11−/− (J), or X11L−/− (K) mice were used as controls. Brain lysates were immunoprecipitated with anti-HCN1 (I), anti-X11 (J), and anti-X11L/Mint2 (K) antibodies. Immunocomplexes were detected by immunoblotting.
selective inhibitor of HCN channel activity (compare lanes 3 through 6). Although we have not confirmed the blockage of channel activity electrophysiologically, ZD7288 had no effect on Aβ levels in cells without HCN1 expression (column 5), and APP expression was not affected by either the presence of HCN1 or by the administration of ZD7288 (Figure 4B, right panel). Furthermore, administration of ZD7288 did not influence the interaction of HCN1 with APP (Additional file 1: Figure S5). These results suggest that the suppression of Aβ generation in HCN1-overexpressing cells probably depends on channel activity (Figure 4B), in agreement with the in vivo observation that the brains of mice lacking the HCN1 gene and with impaired HCN channel activity (Figure 3B, D, and G) demonstrated increased Aβ generation (Figure 4A).

Association of HCN1 with APP in vivo and in vitro
Increased synaptic activity enhances Aβ generation [8-10], and modulation of Aβ generation is not limited to alterations in HCN1 channel activity. Indeed, APP metabolism is thought to be largely regulated by APP-binding partners [14]. Therefore, we next explored the hypothesis that HCN1 might be involved in regulating APP metabolism via a physical interaction between the channel and APP. In support of this hypothesis, an anti-HCN1 antibody co-immunoprecipitated together with HCN1 from a lysate of wild type murine cortex (Figure 5A). The interaction seemed to be specific in that APP was not recovered from the cortical lysate of HCN1-/- mice. The association between APP and HCN1 was next confirmed in the EC. Using EC-rich brain samples isolated from HCN1+/+ and HCN1-/- mice (Additional file 1: Figure S3A), a co-immunoprecipitation assay was performed with an anti-HCN1 antibody, and the immunoprecipitates were analyzed with the indicated antibodies (Figure 5B). Along with X11 and X11L, APP was co-immunoprecipitated with HCN1 in EC-rich brain samples of wild type mice (Figure 5B), suggesting that HCN1 can complex with
APP and X11/X11L in vivo. These results are in agreement with the co-localization results of HCN1, X11, and X11L in the wild type cortex shown above (Figure 3H–K). Tubulin and PSD95 (postsynaptic density protein 95) were not detected in the immunocomplex, indicating the specific association of APP and X11/X11L with HCN1.

To show whether HCN1 directly binds to APP without mediation by X11/X11L, FLAG-APP and HCN1 were transiently expressed in N2a cells and a co-immunoprecipitation

Figure 5 (See legend on next page.)
assay was performed. The anti-FLAG M2 antibody immunoprecipitated HCNI along with FLAG-APP (Figure 5C). An anti-hAPP extracellular domain antibody (LN27) also recovered HCNI (Figure 5D), and anti-HCN1 antibody recovered FLAG-APP (Figure 5E).

APP is a type I transmembrane protein composed of a large extracellular (luminal) domain of 596 amino acids and a small intracellular domain of 47 amino acids. On the other hand, HCNI is a six-transmembrane protein with short extracellular sequences between transmembrane regions one and two, three and four, and five and six, and long intracellular domains within the amino- and carboxyl-terminal regions of the protein. To determine the region of APP that binds to HCNI, we performed co-immunoprecipitation assays using APP deletion mutants (C99-FLAG, which largely lacks the extracellular domain of APP and in which FLAG is fused to the carboxyl terminal region of APP, and APPΔcyt, which lacks the 43-amino-acid carboxyl terminal region of APP) (Figure 5F, G). The results of this assay indicated that HCNI was not co-immunoprecipitated with C99-FLAG (Figure 5F), whereas APPΔcyt was co-immunoprecipitated with HCNI (Figure 5G).

Next, we performed an in vitro pull-down assay with FLAG-soluble APP (FLAG-sAPP, consisting of the extracellular domain of APP cleaved at the α- and/or β-cleavage sites). FLAG-sAPP was purified with affinity beads (anti-FLAG M2 affinity gel) from the culture medium of N2a cells expressing FLAG-APP (Figure 5H) and then incubated with lysates of N2a cells that expressed HCNI. HCNI bound to FLAG-sAPP, but not to FLAG-tag alone (Figure 5I). Taken together, the results shown in Figure 5 indicate that HCNI associates with APP through its extracellular (luminal) domain.

Hence, HCNI apparently interacts with the extracellular domain of APP (Figure 5) and with both X11 and X11L in the cytoplasm (Figure 3H–K, Figure 5B). This suggests that the HCNI channel might form a ternary complex with APP and either X11 or X11L to regulate Aβ generation. However, the detailed molecular regulation of complex formation remains to be determined.

Age- and AD state-dependent HCN disruption in the temporal cortex (superior temporal gyrus) of cynomolgus monkeys and sporadic AD patients

Advanced age is the greatest risk factor for AD. To examine the relationship between aging and HCNI levels, we quantified the amount of HCNI, Aβ, APP, and actin in freshly frozen brain tissues (superior temporal gyrus) from cynomolgus monkeys of various ages (Figure 6A and Additional file 1: Figure S6). Senile plaques and neurofibrillary tangles spontaneously appear in the brains of cynomolgus monkeys with advancing age [32,33], and the amino acid sequence of Aβ in cynomolgus monkeys is identical to that in humans [34]. Thus, we hypothesized that the cynomolgus monkey would be a useful animal model for investigating the relationship between aging and AD pathology. Significant negative correlations were found between HCNI levels and age (n = 39, r = −0.5363, p = 0.0004) (Figure 6A, left), between HCNI and APP levels (n = 39, r = −0.3796, p = 0.0086) (Additional file 1: Figure S6B), between HCNI and TBS-insoluble Aβ40 levels (n = 39, r = −0.2878, p = 0.0421) (Additional file 1: Figure S6C and D), and between HCNI and Tris buffered saline (TBS)-insoluble Aβ42 levels (n = 39, r = −0.296, p = 0.0401) (Additional file 1: Figure S6E and F). A significant positive correlation was found between age and APP level (n = 39, r = 0.8156, p < 0.0001) (Additional file 1: Figure S6A), and a significant weak-positive correlation was found between APP and TBS-insoluble Aβ42 levels (n = 39, r = 0.3714, p = 0.0236) (Additional file 1: Figure S6H). However, no correlation was found between age and actin level (n = 39, r = −0.1981, p = 0.2266) (Figure 6A, right) or between APP and TBS-insoluble Aβ40 levels (n = 39, r = 0.2993, p = 0.072) (Additional file 1: Figure S6G).

Finally, we examined the possibility of altered HCNI levels in human AD brain specimens obtained at autopsy.
The postmortem time was not significantly different for the AD and non-AD brain samples used in this study (non-AD: n = 13, AD: n = 12, p = 0.8066), and no significant decrease in HCN1 levels related to postmortem time was observed (n = 25, r = -0.2416, p = 0.2446) (Figure 6C and Table 1). Of great relevance to this study, the amount of HCN1 was significantly reduced in AD brains (superior temporal gyrus) compared with that in age-matched control brains (non-AD: n = 13, AD: n = 12, p = 0.0083), while the levels of APP and actin were not significantly altered (Figure 6B and Table 1). These results suggest that the reduction in HCN1 expression that occurs with age (Figure 6A) may be involved in the aggravation of the pathology of AD.

**Discussion**

X11 and X11L are well-characterized neural adaptor proteins that regulate the trafficking and metabolism of APP [14]. Many reports indicate that X11s bind to APP and suppress Aβ generation in vitro and in vivo [14-22]. Furthermore, X11s are thought to mediate a number of cellular functions through their association with various proteins [35]. This report showed that mutant mice lacking both X11 and X11L present with dysfunctional HCN1 channel activity and epileptic seizures. Notably, AD patients are also at increased risk of epileptic seizures. Furthermore, mutant mice lacking HCN1 demonstrated increased generation of Aβ, which is a causative factor for the development of AD.

The incidence of AD dramatically increases with age. We found that the amount of HCN1 decreased with both aging and in AD. The dysfunction of HCN1 that occurs over time may, thus, be a trigger for epileptic seizures and the pathogenic generation of Aβ in AD.

Several converging studies corroborate the premise that HCN channel activity is closely related to epileptogenesis [11]. For example, HCN1 expression is significantly reduced in the EC after temporal lobe epilepsy [36,37]. Furthermore, HCN1 channel plasticity in cortical neurons is similar in multiple epileptic animal models [38-43]. Moreover, kainic acid-induced seizure susceptibility is increased in HCN1-/- mice [27], and HCN2-deficient mice exhibit spontaneous absence seizures [26].

HCN1-/- mice show a significantly higher number of negative resting membrane potentials and a significantly higher input resistance measured from responses to either negative or positive current steps [28]. As such, seizure susceptibility is increased in HCN1-/- mice [27], indicating that loss of the HCN1 subunit enhances neuronal excitability, which can increase Aβ generation [8-10]. These observations suggest that enhanced Aβ generation in HCN1-/- mice results from neuronal hyper-excitability, which is in turn caused by ablation of the HCN1 gene.
On the other hand, the present study showed that HCN1 physically associated with APP through the extracellular domain of APP. Therefore, HCN1-mediated regulation of Aβ generation may depend on a molecular linkage between HCN1 and APP and not simply on alterations in neuronal excitability. However, the molecular mechanism by which HCN1 potentially links epileptic seizures to Aβ generation in AD remains to be elucidated.

Our results suggest that ablation of X11/X11L induces aberrant HCN1 distribution and function along with epilepsy. Although the molecular mechanism by which X11s regulates HCN channel activity also remains unclear, X11s are known to modulate intracellular trafficking of membrane proteins. For example, X11s interact with certain proteins implicated in traffic and transport, such as Arfs, Rab6, and KIF17 [29,44,45]. Furthermore, X11s bind to vesicular cargo proteins, such as APP and alcadein [16,46,47] and regulate the intracellular distribution of APP [21,30]. We hypothesize that X11 and X11L similarly influence the trafficking and/or intracellular localization of HCN1. We further hypothesize that the mislocalization of HCN1 observed in X11−/−/ X11L−/− mice (Additional file 1: Figure S4) may cause aberrant excitatory neuronal activities, resulting in epileptic seizures.

In conclusion, this study indicates that HCN1 may play an important role in the regulation of neuronal

---

**Table 1 Summary of subject information presented in Figure 6B and C**

| Sample no. | Subject | Age | Sex | Post mortem time (min) | Braak stage | Seizure | Relative ratio (protein/tubulin) |
|------------|---------|-----|-----|------------------------|-------------|---------|---------------------------------|
| 1          | Normal  | 84  | F   | 877                    | 1           | -       | 0.929 1.192 0.809              |
| 2          | Normal  | 88  | F   | 144                    | 1           | -       | 0.856 1.046 0.859              |
| 3          | Normal  | 70  | M   | 340                    | 0.5         | -       | 0.955 1.189 0.859              |
| 4          | AD      | 84  | M   | 71                     | 4           | -       | 0.950 1.171 0.952              |
| 5          | AD      | 70  | M   | 276                    | 4           | -       | 0.829 0.986 0.716              |
| 6          | AD      | 74  | M   | 322                    | 5           | -       | 0.961 0.990 0.827              |
| 7          | AD      | 75  | M   | 594                    | 6           | -       | 1.069 1.176 0.589              |
| 8          | AD      | 76  | M   | 947                    | 6           | +       | 1.190 1.167 0.273              |
| 9          | AD      | 79  | F   | 203                    | 5           | -       | 1.019 0.913 0.317              |
| 10         | AD      | 81  | M   | 360                    | 6           | -       | 0.971 0.862 0.247              |
| 11         | AD      | 81  | F   | 442                    | 5           | -       | 0.971 0.862 0.385              |
| 12         | AD      | 82  | F   | 254                    | 6           | -       | 0.988 1.029 0.313              |
| 13         | AD      | 82  | F   | 533                    | 5           | -       | 0.988 1.001 0.566              |
| 14         | AD      | 82  | F   | 338                    | 4           | -       | 1.028 1.063 0.770              |
| 15         | AD      | 84  | M   | 590                    | 5           | -       | 1.071 1.128 0.876              |
| 16         | Normal  | 78  | F   | 87                     | 2           | -       | 1.108 1.138 2.153              |
| 17         | Normal  | 81  | M   | 134                    | 1           | -       | 1.122 0.971 0.902              |
| 18         | Normal  | 82  | F   | 148                    | 1           | -       | 1.178 1.109 1.963              |
| 19         | Normal  | 82  | F   | 155                    | 2           | -       | 1.141 1.026 0.821              |
| 20         | Normal  | 80  | M   | 317                    | 2           | -       | 1.254 1.037 0.893              |
| 21         | Normal  | 80  | M   | 510                    | 2           | -       | 1.071 0.778 0.669              |
| 22         | Normal  | 82  | M   | 530                    | 1           | -       | 0.979 0.916 0.384              |
| 23         | Normal  | 78  | M   | 575                    | 1           | -       | 0.905 1.007 0.713              |
| 24         | Normal  | 78  | M   | 690                    | 1           | -       | 0.784 0.986 1.479              |
| 25         | Normal  | 82  | M   | 736                    | 1           | -       | 0.774 0.743 1.448              |

Postmortem brain samples were obtained from the Brain Bank for Aging Research, Tokyo Metropolitan Institute of Gerontology. Experimental procedures were approved by the appropriate ethical boards at each institute. Autopsies were performed with written informed consent from the patients or their relatives. The clinical diagnosis of AD was based on two major criteria: the Diagnostic and Statistical Manual of Mental Disorders: 4th Edition (DSM-IV) and the National Institute of Neurological and Communicational Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA). The neuropathological diagnosis of AD was made using Consortium to Establish a Registry for Alzheimer’s Disease criteria (average age at death, 79.2 ± 4.4 years). Control brains were obtained from age-matched individuals with no history of neurological or psychiatric illness (average age at death, 80.4 ± 4.2 years). Subjects, age, gender, postmortem time, Braak stage, seizure history, and relative protein/tubulin ratios are indicated.
activity, along with Aβ generation in the hippocampal formation. However, we cannot rule out the possibility that additional ion channels (e.g., M-channels, Kir-channels, and sodium leak channels) also participate in the regulation of APP metabolism. Taken together, the current observations may provide new insights into the mechanisms underlying the linkage between epileptic seizures and Aβ generation in AD.

Methods

Animals and human non-AD and AD brain samples
All animal studies were conducted in compliance with the guidelines of the Animal Studies Committees of Hokkaido University (Sapporo, Japan), Shiga University (Shiga, Japan), and the National Institute of Biomedical Innovation (Osaka, Japan). Mice were maintained under a 12-h light/12-h dark cycle (lights on, 7:00 A.M.–7:00 P.M.), and provided with food and water ad libitum. X11+/+X11L+/+, X11+/+X11L−/−, and X11−/−X11L−/− mice have already been described [20,21]. HCN−/− mice (stock number 005034) were purchased from The Jackson Laboratory (Bar Harbor, Maine). Male mice were used for all experiments.

Brain samples containing the superior temporal gyrus of cynomolgus monkeys (Macaca fascicularis) were obtained from Shiga University of Medical Science and the National Institute of Biomedical Innovation. The monkeys were housed in individual cages prior to the experiment and were maintained according to institutional guidelines for experimental animal welfare. Human brain samples containing the superior temporal gyrus (Broadmann area 22) were obtained from the Brain Bank for Aging Research, the Tokyo Metropolitan Institute of Gerontology (Itabashi, Tokyo, Japan). Human temporal cortical specimens for the quantification of proteins were obtained from brains that were removed, processed, and stored at −80°C within 16 h postmortem at the Brain Bank at Tokyo Metropolitan Institute of Gerontology. (Patients were placed in a cold (4°C) room within 2 h of death.) For all brains registered at the bank, written informed consent for their use for medical research was obtained from the patient prior to death or from the patient’s family. Brain specimens were collected from Broadmann area 22 (superior temporal gyrus) for 12 AD patients (79.2±4.4 years of age) and 13 control patients (80.4±4.2 years of age) [48]. Detailed descriptions of all subjects, including the relative protein/tubulin ratio for each individual, are shown in Table 1.

Antibodies

Polyclonal rabbit anti-HCN1 antibody [25] and polyclonal rabbit anti-X11 UT153 antibody [21] have already been described. Monoclonal mouse anti-tubulin DM1A antibody and polyclonal rabbit anti-c-Fos, rabbit anti-Egr-1, and goat anti-HCN1 antibodies (sc-19706) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Characterization and demonstration of the antigen-specificity of the goat anti-HCN1 antibody (sc-19706) is shown in Additional file 1: Figure S7. Monoclonal mouse anti-X11L/mint2 and anti-PSD95 antibodies were purchased from BD Transduction Laboratories (Lexington, KY, USA). Anti-actin antibody and the anti-HCN1 antibody, AB5884, were purchased from Millipore (Billerica, MA, USA). Anti-FLAG M2 and polyclonal rabbit anti-APP cytoplasmic domain (N-terminus) antibodies were purchased from Sigma-Aldrich (St. Louis, MO, USA), and the anti-human APP extracellular domain antibody (LN27) was purchased from Zymed (San Francisco, CA, USA). Anti-FLAG M2 affinity gel and FLAG peptide were purchased from Sigma-Aldrich.

Plasmid construction

Human APP695 (hAPP695) and FLAG-APP695 cDNA were inserted into the pcDNA3 plasmid at the HindIII/XbaI restriction sites to produce pcDNA3-hAPP695 and pcDNA3-FLAG-hAPP695 [46]. The cDNA constructs pcDNA3-hAPPΔcyt (in which amino acids 652–695 of hAPP695 are deleted) and pcDNA3.1-C99-FLAG (in which the signal sequence of hAPP is inserted into the 5′ region of C99) were generated by PCR using pcDNA3-hAPP695 as the template. The generated fragments were ligated into pcDNA3-hAPP695 and pcDNA3.1-FLAG at the BamHI/XbaI restriction site and the HindIII/XbaI restriction site, respectively. The pCI-murine HCN1 vector was a kind gift from Dr. Takahiro M. Ishii [49].

Immunohistochemistry

Murine brain tissue sections were prepared and incubated with primary antibodies as described [21]. The sections were further incubated with goat anti-rabbit IgG antibodies conjugated to biotin (Vector Laboratories, Burlingame, CA, USA), followed by the ABC complex. Peroxidase activity was revealed using diaminobenzidine as the chromogen. Alternatively, sections were incubated with donkey anti-mouse IgG coupled with Alexa Fluor 488, donkey anti-rabbit IgG coupled with Cy3, or donkey anti-goat IgG coupled with Alexa Fluor 633 in phosphate buffered saline (PBS) containing 3% bovine serum albumin (BSA) for 2 h at room temperature. Sections were mounted onto slides with Shandon Immu-Mount (Thermo, Pittsburgh, PA, USA) and viewed under a BZ-9000 microscope (Keyence, Woodcliff Lake, NJ, USA).

Immunoblotting and co-immunoprecipitation analysis

The cortices of wild type, X11+/+X11L+/+, X11+/+X11L−/−, X11−/−X11L−/−, HCN1+/+, and HCN1−/− mice, and cynomolgus monkey brains (superior temporal gyrus) and human post-mortem brains (superior temporal gyrus) were homogenized in eight volumes of radioimmune
precipitation assay buffer containing 0.5% (w/v) sodium dodecyl sulfate (SDS) and a protease inhibitor mixture (5 μg/ml chymostatin, 5 μg/ml leupeptin, and 5 μg/ml pepstatin). The homogenates were lysed by sonication on ice and centrifuged at 20,000 × g for 10 min at 4°C. The resulting supernatants were used for immunoblot analysis. Proteins (10 μg per lysate) were separated via SDS (w/v) polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5% (w/v) polyacrylamide gels.

The cortex (from one mouse) and EC-rich region (from five mice) from wild type and gene-null mice were homogenized in eight volumes of HBS-T lysis buffer (10 mM HEPES [pH 7.6] containing 150 mM NaCl, 5 mM EDTA, 0.5% [v/v] Triton X-100, 5 μg/ml chymostatin, 5 μg/ml leupeptin, and 5 μg/ml pepstatin A). Homogenates were then centrifuged at 20,000 × g for 10 min at 4°C. N2a cells (~1 × 10⁶) were transiently transfected with 0.8 μg pcDNA3-FLAG-hAPP695, pcDNA3-hAPP695, pcDNA3-hAPPΔC90 or pcDNA3.1-C99-FLAG and 0.4 μg of pCI-murine HCN1 using Lipofectamine 2000 (Invitrogen) and cultured for 24 h in medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS). Cells were harvested, lysed in lysis buffer (PBS containing 1.0% [v/v] Triton X-100, 5 μg/ml chymostatin, 5 μg/ml leupeptin, and 5 μg/ml pepstatin A), and centrifuged for 5 min at 4°C. The resulting supernatants were incubated with anti-FLAG M2, anti-hAPP extracellular domain (LN27), anti-HCN1, anti-X11, or anti-X11L/Mint2 antibody at 4°C for 2 h. Each immunocomplex was recovered with Dynabeads® Protein G (Invitrogen) and washed three times with lysis buffer. The proteins were separated on 7.5% (w/v) polyacrylamide gels, transferred onto nitrocellulose membranes, and analyzed by immunoblotting with the indicated antibodies. The immunoreactants were detected using the ECL plus™ detection system (GE Healthcare) and quantified using a Versa Doc model 3000 (Bio-Rad).

**Affinity purification of FLAG-sAPP from N2a conditioned medium and immunoprecipitation of APP-HCN1 complex**

N2a cells (~8.8 × 10⁶) were transiently transfected with 5 μg pcDNA3-FLAG-hAPP695 using Lipofectamine 2000 (Invitrogen) and cultured for 24 h in 8 mL of medium (DMEM) containing 10% (v/v) FBS. FLAG-sAPP was collected from the conditioned culture medium by using 50 μL of anti-FLAG M2 affinity gel. The collected FLAG-sAPP that was bound to the gel was washed twice with wash buffer I (20 mM Tris–HCl [pH 8.0], 1 M NaCl, and 0.1% Triton X-100) and twice with wash buffer II (50 mM Tris–HCl [pH 8.0], 150 mM NaCl, 1% Triton X-100, 0.05% SDS, and 5 mM EDTA). Collected FLAG-sAPP was then eluted from the affinity gel with 20 μg FLAG-peptide and subjected to immunoblotting and Coomassie brilliant blue (CBB) staining to ascertain the degree of purification.

FLAG-sAPP or FLAG-peptide coupled to anti-FLAG M2 affinity beads were then incubated for 2 h at 4°C with HBS-T-soluble lysates derived from wild type N2a cells or N2a cells transiently overexpressing HCN1. The beads were washed three times with HBS-T lysis buffer. The proteins bound to the beads were separated on 7.5% (w/v) polyacrylamide gels, transferred onto membranes, and analyzed by immunoblotting with the indicated antibodies. The immunoreactants were detected using the ECL plus™ detection system (GE Healthcare) and quantified using a Versa Doc model 3000 (Bio-Rad).

**Quantification of Aβ40 and Aβ42**

Endogenous murine Aβ was measured as described previously [21] using cortices dissected from 4-month-old mice. Murine Aβ40 and Aβ42 were measured using a sandwich ELISA (sELISA) system (mouse/rat Aβ40 and Aβ42 assay kit, Immuno-Biological Laboratories (IBL), Fujikyo, Japan). N2a cells (~2 × 10⁶) were transiently transfected with 0.2 μg pcDNA3-FLAG-hAPP695 and 0.1 μg pCI-murine HCN1 using Lipofectamine 2000 (Invitrogen) and cultured in medium (DMEM) containing 10% (v/v) FBS. After 24 h, cells were incubated in fresh medium for an additional 4 h with or without 10 μM ZD7288 (Tocris Bioscience, Bristol, UK). Human Aβ40 (hAβ40) and hAβ42 secreted into the culture medium during the 4-h incubation were quantified using the sELISA system.

**Electroencephalogram recording**

To obtain free-moving cortical electrocorticogram recordings, recording and reference electrodes were screwed onto the skull over the temporal (anterior = –3.1 mm, lateral = 2.5 mm, relative to bregma) and occipital regions of the murine brain. Recordings were continuously made using a cortical electroencephalogram linked to a telemetry system (Unimec, Usmate Velate, Italy) throughout the experiment [50].

**In current recording**

All experiments were performed in a blinded manner. Mice (12–14 weeks old) were anesthetized with halothane (Takeda Chemical Industries) and then sacrificed by decapitation. The brain was rapidly removed and immediately placed in a cold (4°C) cutting solution, which contained 234 mM sucrose, 2.5 mM KCl, 1.1 mM NaH2PO4, 10 mM MgSO4, 26 mM NaHCO3, 12 mM glucose, and 0.5 mM CaCl2. Horizontal slices (300 μm thick), which included the EC and the hippocampus, were prepared using a vibratome (VT1000S, Leica, Nussloch, Germany). During recording, individual slices were transferred to a submerged recording chamber and continuously perfused with artificial cerebrospinal fluid (ACSF) maintained at 30–32°C. The ACSF contained 125 mM
NaCl, 2.5 mM KCl, 1.1 mM NaH₂PO₄, 1.0 mM MgSO₄, 26 mM NaHCO₃, 12 mM glucose, and 2.0 mM CaCl₂ and was saturated with 95% O₂ and 5% CO₂. Whole-cell patch-clamp recordings were obtained from principal excitatory cells in layer II of the EC. The patch pipettes were filled with an intracellular solution containing 30 mM K-methanesulfonate, 6 mM NaCl, 0.2 mM EGTA, 10 mM HEPES, 4 mM Mg-ATP, 0.3 mM Na₃-GTP, and 10 mM phosphocreatine-Tris (pH 7.3). In layer II cells of the EC, the hyperpolarization-induced and “slowly-activating” inward currents in the voltage-clamp mode mainly consisted of Ih currents [51]. When Ih currents were studied in the voltage-clamp mode, membrane potentials were first held at ~65 mV, and then voltage steps with a duration of 7 s were applied from ~55 mV to ~125 mV (10 mV increments), after which the holding potentials were allowed to return to ~65 mV to obtain the tail currents. The amplitudes of the tail currents at 50 ms after the end of the final voltage step were analyzed to obtain the Ih currents. In all electrophysiological analyses, pooled data were represented as the mean ± SEM.

Statistical analysis
Statistical analyses were performed using a two-tailed Mann–Whitney U-test, a one-way analysis of variance followed by Tukey’s multiple comparison test, or the two-tailed Pearson’s correlation coefficient. All analyses were conducted with GraphPad Prism 5 software.

Additional files

Additional file 1: Figure S1. Simultaneous recording of electrocorticogram in epilepsy model mouse and corresponding movie. A representative electrocorticogram recorded during the interictal period in 13-week-old X11+/+ X11L+/+ mice (n = 4) is shown. The undefined region indicates the time frame of the corresponding movie (Movie S3).

Figure S2. Individual data of Ih currents density in entorhinal cortex layer II neurons of wild-type and X11s-null mice. (A) Individual data of Ih current density. Blue indicate the data of mouse #1 and red indicate mouse #2. (B) Mean, SD, MEAN, and count number of A. P Value of Student’s t-test (#1 vs #2) shown in bottom line. (C) Distribution and average of current density of A. Closed symbols indicate data of mouse #1 and opened symbols indicate mouse #2 (mean ± SEM).

Figure S3. HCN1 levels in the EC-rich region of the brains of X11+/+ X11L+/+ and X11s mutant mice. (A) Isolation of the EC-rich region from a horizontal slice (300 μm thick) of murine brain. Brain slices from 13-week-old X11+/+ X11L+/+, X11s/+ X11L+/+, X11s-/+ X11L+/+, and X11s-/ X11L+/+ mice were prepared in ice-cold PBS using a vibratome (VT1200S; Leica) (left panel). The EC-rich region (EC) was separated from each slice as indicated (right panel). (B, C) Quantification of HCN1 in the EC-rich region. Horizontal slices were homogenized in eight volumes of radioimmunoprecipitation assay buffer containing 0.5% (w/v) SDS and a protease inhibitor mixture (5 μg/ml chymostatin, 5 μg/ml leupeptin, and 5 μg/ml pepstatin), subjected to sonication on ice, and centrifuged at 20,000 × g for 10 min at 4°C. (B) The resulting supernatants (each containing 10 μg protein) were analyzed by SDS-PAGE on 7.5% (w/v) polyacrylamide gels, followed by immunoblotting with anti-HCN1, anti-X11, anti-X11L, and anti-tubulin antibodies (n = 4). (C) The HCN1 level was normalized to the tubulin level to give the relative HCN1/tubulin ratio for each genotype (mean ± SEM, n = 4). (D) Figure S4. Altered distribution of the HCN channel in X11s-/-/X11L-/- mice. (A) Low-power images of horizontal brain sections from 13-week-old wild type (X11+/+ X11L+/+, upper panel) and X11s-/ X11L+/+ (Lower panel) mutant mice were immunostained with an anti-HCN1 antibody (n=3). Scale bar, 300 μm. (B) Representative high-resolution images of horizontal brain sections from 13-week-old X11+/+ X11L+/+ (a, d) and X11s-/-/X11L-/- (b, d) mice were subjected to immunostaining with an anti-HCN1 antibody (a and b) and Nissl stain (c and d). (C) Quantitative analysis of HCN1 immunoreactivity in the EC of 13-week-old wild type (X11+/+ X11L+/+) and X11s-/-/X11L-/- mutant mice. The intensity of the HCN1 immunoreactivity in the areas enclosed by the open boxes in A was measured using NIH Image J software. Scale bar, 50 μm.

Figure S5. Complex formation of HCN1 with APP in N2a cells treated with ZD7288. FLAG-APP and HCN1 were transiently overexpressed in N2a cells (+/−) or without (−) 10 μM ZD7288. To standardize the amount of plasmid transfected into the cells, an empty vector (−) was added to yield 1.2 μg of plasmid in total. The cell lysates were subjected to immunoprecipitation with anti-FLAG M2 antibody. Immunocomplexes were detected by immunoblotting with anti-HCN1 and anti-FLAG antibodies. (Figure S6) Covariance analysis of various protein levels in the brains of cynomolgus monkeys. A) Quantitative analysis of HCN1 (n = 39, r = 0.3714, *p = 0.0236). Statistical analysis was performed using the two-tailed Pearson’s correlation coefficient. (Figure S7) Specificity of the polyclonal goat anti-HCN1 antibody. (A) Competition analysis using glutathione-S-transferase (GST) fused to the 60-amino acid carboxyl-terminal region of murine HCN1 (mHCN1 C60). This region of the protein contains the epitope for the goat anti-HCN1 antibody used in this study (sc-19706; Santa Cruz Biotechnology). Brain lysates (10 μg protein) derived from HCN1+/+ and HCN1−/− mice and cynomolgus monkeys were subjected to immunoblot analysis. The anti-HCN1 antibody was pre-incubated with 20 μg GST alone or GST-mHCN1 C60 recombinant protein at 4°C for 2 h. The pre-incubated antibody was then reacted with the immunoblots. HCN1−/− was detected in HCN1+/+ mouse and monkey brains when the antibody was pre-incubated with GST alone, but not when the antibody was pre-incubated with GST-mHCN1 C60. (B) Titir comparison between anti-HCN1 antibodies. Brain lysates (10 μg protein) were subjected to immunoblot analysis with two commercial anti-HCN1 antibodies (sc-19706, Santa Cruz Biotechnology; and AB5884, Millipore) (sc-19706: Santa Cruz Biotechnology). Brain lysates (10 μg protein) derived from HCN1+/+ and HCN1−/− mice and cynomolgus monkeys were subjected to immunoblot analysis. The anti-HCN1 antibody was pre-incubated with 20 μg GST alone or GST-mHCN1 C60 recombinant protein at 4°C for 2 h. The pre-incubated antibody was then reacted with the immunoblots. HCN1−/− was detected in HCN1+/+ mouse and monkey brains when the antibody was pre-incubated with GST alone, but not when the antibody was pre-incubated with GST-mHCN1 C60. (C) Specificity of goat anti-HCN1 antibody (sc-19706) for immunohistochemical analysis. (a, b) Representative images of horizontal brain sections showing the hippocampal formation in 13-week-old X11+/+ (a) and X11s−/− (b) mice stained with goat anti-HCN1 antibody, followed by donkey anti-goat IgG coupled with FITC. (c, d) Magnified view of the squares in (a) and (b). HCN1 signals (green) observed in HCN1+/+ mouse (c) and counter-stained with DAPI are shown in blue. Scale bars, 300 μm (a, b), 50 μm (c, d).
Abbreviations

ACSF: Artificial cerebrospinal fluid; AD: Alzheimer’s disease; APP: Amyloid precursor protein; Aβ: Amyloid β peptide; DG: Dentate gyrus; EC: Entorhinal cortex; FBS: Fetal bovine serum; HCN channel: Hyperpolarization-activated cyclic nucleotide gated channel; Ih current: Hyperpolarization-activated current; PBS: Phosphate buffered saline; sAPP: Soluble APP; SDS: Sodium dodecyl sulfate; eELISA: Sandwich ELISA; SDS-PAGE: SDS polyacrylamide gel electrophoresis; TBS: Tris buffer saline; X11L: X11-like; X11L2: X11-like2; X1ts: X11 proteins.

Competing interests

The authors declare no competing interests.

Authors’ contributions

YS, TI, GZ, MO, KI, SK and TS generated the hypotheses for the mouse, monkey and human projects. YS and NK performed the biochemical and histochemical analyses for the mouse and monkey studies. YS, MN and TS drafted the manuscript. YS, TI, GZ, MO, KI, SK and TS edited the manuscript and contributed to discussion. YS and NK performed the biochemical and histochemical analyses for the mouse and monkey studies. YS, MN and SM performed biochemical analyses for the human study. TI and KI conducted electrophysiological analyses for the mouse study. YS, GZ, MO and SK performed electrophencereograph recordings. MN and NK provided monkey tissues, and SM provided human tissues. All authors read and approved the final manuscript.

Acknowledgements

This study was supported in part by a Grant-in-Aid for Research Activity Start-up (21890002) and by a Grant-in-Aid for Young Scientists (B) (23790069) from the Japan Society for the Promotion of Science (JSPS) to YS. YS was also supported by the Akiyama Life Science Foundation and the Regional R&D Proposal-Based Program from the Northern Advancement Center for Science & Technology of Hokkaido, Japan. TS was supported in part by Grants-in-aid for Scientific Research (23390011, 2311370, 22659011) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, and by a grant from the Ministry of Health, Labor and Welfare (MHLW) of Japan.

Author details

1Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kitaku-ku, Sapporo 060-0012, Japan.
2Laboratory of Neurobiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8530, Japan.
3Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
4Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan.
5Molecular Neurosciences Research Center, Shiga University of Medical Science, Otsu 520-2192, Japan.
6Laboratory of Disease Control, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Tsukuba 305-0843, Japan.
7Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo 173-0015, Japan.
8Brain Bank for Aging Research, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo 173-0015, Japan.
9Departments of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki 036-8562, Japan.
10Division of Cerebral Structure, National Institute for Physiological Sciences, Okazaki 444-8585, Japan.
11Department of Information Physiology, National Institute for Physiological Sciences, Okazaki 444-8787, Japan.

Received: 12 April 2012 Accepted: 27 September 2012

References

1. Selkoe DJ: Alzheimer’s disease is a synaptic failure. Science 2002, 298:799–791.
2. Hauser WA, Monis M, Heston LL, Anderson VE: Seizures and myoclonus in patients with Alzheimer’s disease. Neurology 1986, 36:1216–1230.
3. Horsford DC, Hauser WA, Annegers JF, Koremen E, Rocca WA: Dementia and adult-onset unprovoked seizures. Neurology 1996, 46:727–730.
4. Mendez M, Lim G: Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 2003, 20:791–803.
5. Arntniek JC, Hauser WA, DelCastillo Gastaneda C, Jacobs DM, et al: Incidence and predictors of seizures in patients with Alzheimer’s disease. Epilepsia 2006, 47:867–872.
6. Lozada DA, Larner AJ: Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer’s disease. Dement Geriatr Cogn Disord 2002, 22:127–129.
7. Marcon G, Giaccone G, Cupidi C, Balestriere M, Beltrami CA, et al: Neuropathological and clinical phenotype of an Italian Alzheimer family with M239V mutation of presenilin 2 gene. J Neuropathol Exp Neurol 2004, 63:199–209.
8. Kamietz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, et al: APP processing and synaptic function. Neuron 2003, 37:925–937.
9. Cinto JR, Yamada KA, Finn MB: Slow spike and wave activity: Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005, 48:913–922.
10. Cinto JR, Kang JE, Lee J, Stewart FR, Verges DK, et al: Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 2008, 58:42–51.
11. Postea O, Biel M: Exploring HCN channels as novel drug targets. Nat Rev Drug Discov 2011, 10:933–941.
12. Noam Y, Bernald C, Baram TZ: Towards an integrated view of HCN channel role in epilepsy. Curr Opin Neurobiol 2011, 21:873–879.
13. Kimura K, Kitano J, Nakajima Y, Nakanishi S: Hyperpolarization-activated cyclic nucleotide-gated HCN2 cation channel forms a protein assembly with multiple neuronal scaffold proteins in distinct modes of protein-protein interaction. Genes Cells 2004, 9:631–640.
14. Suzuki T, Nakaya T: Regulation of amyloid β-peptide precursor by phosphorylation and protein interaction. J Biol Chem 2008, 283:29633–29637.
15. Borg JP, Yang Y, De Taddeo Borg M, Margolis B, Turner RS. The X1alpha protein slows cellular amyloid precursor protein processing and reduces Abeta40 and Abeta42 secretion. J Biol Chem 1998, 273:14761–14766.
16. Tomita S, Ozaki T, Tatu H, Oguchi S, Takeda S, et al: Interaction of a neuron-specific protein containing PDZ domains with Alzheimer’s amyloid precursor protein. J Biol Chem 1999, 274:2243–2254.
17. Lee JH, Lau KF, Perkinton MS, Standen CL, Shemilt SJ, et al: The Neuronal Adaptor Protein X11a reduces Aβ Levels in the Brains of Alzheimer’s APPswe Tg2576 Transgenic Mice. J Biol Chem 2003, 278:47025–47039.
18. Lee JH, Lau KF, Perkinton MS, Standen CL, Rogeli B, et al: The neuronal adaptor protein X11 beta reduces amyloid beta-protein levels and amyloid plaque formation in the brains of transgenic mice. J Biol Chem 2004, 279:40099–41910.
19. Mitchell JC, Arff BB, Yates DM, Lau KF, Perkinton MS, et al: X11 beta rescues memory and long-term potentiation deficits in Alzheimer’s disease APPswe Tg2576 mice. Hum Mol Genet 2009, 18:4392–4400.
20. Sano Y, Sano Y, Syuzo-Takabatake A, Nakaya T, Saito Y, Tomita S, et al: Enhanced amyloidogenic metabolism of the amyloid beta-protein precursor in the X11l-deficient mouse brain. J Biol Chem 2006, 281:37853–37860.
21. Saito Y, Sano Y, Vassar R, Gandy S, Nakaya T, et al: X11 proteins regulate the translocation of amyloid beta-protein precursor (APP) into detergent-resistant membrane and suppress the amyloidogenic cleavage of APP by beta-site-cleaving enzyme in brain. J Biol Chem 2008, 283:35763–35771.
22. Kondo M, Shiono M, Itoh G, Takei N, Matushima T, et al: Increased amyloidogenic processing of transgenic human APP in X11-like deficient mouse brain. Mol Neurodegener 2010, 5:35.
23. Morimoto K, Fahnestock M, Racine RJ: Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol 2004, 73:56–160.
24. van Strien NM, Cappaert NL, Witter MP: The anatomy of memory: an interactive overview of the parahippocampal–hippocampal network. Nat Rev Neurosci 2009, 10:272–282.
25. Notomi T, Shimamoto R: Immunohistochemical localization of Ih channel subunits, HCN1-4, in the rat brain. J Comp Neurol 2004, 471:241–276.
26. van Strien NM, Cappaert NL, Witter MP: The anatomy of memory: an interactive overview of the parahippocampal–hippocampal network. Nat Rev Neurosci 2009, 10:272–282.
27. Huang Z, Walker MC, Shah MM: Loss of dendritic HCN1 subunits enhances cortical excitability and epileptogenesis. J Neurosci 2009, 29:10979–10988.
28. Nolan MF, Dudman JT, Dodson PD, Santoro B: HCN1 channels control resting and active integrative properties of stellate cells from layer II of the entorhinal cortex. J Neurosci 2007, 27:12440–12451.

29. Setou M, Nakagawa T, Seog DH, Hirokawa N: Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor-containing vesicle transport. Science 2000, 288:1796–1802.

30. Saito Y, Akiyama M, Araki Y, Sumioka A, Shiono M, et al: Intracellular Trafficking of the Amyloid β-Protein Precursor (APP) Regulated by Novel Function of X11-Like. PLoS One 2011, 6:e22108.

31. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239–259.

32. Nakamura S, Nakayama H, Goto N, Ono F, Sakakibara I, Yoshikawa Y: Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys. J Med Primatol 1998, 27:244–252.

33. Okawa N, Kimura N, Yanagisawa K: Alzheimer-type tau pathology in advanced aged nonhuman primate brains harboring substantial amyloid deposition. Brain Res 2010, 1315:137–149.

34. Podlisny MB, Tolan DR, Selkoe DJ: The homology of the amyloid β protein precursor in monkey and human supports a primate model for β amyloidosis in Alzheimer's disease. Am J Pathol 1991, 138:1423–1435.

35. Rogelj B, Mitchell JC, Miller CCJ, McLoughlin DM: The X11/Mint family of adaptor proteins. Brain Res Rev 2006, 52:305–315.

36. Shah MM, Anderson AE, Leung V, Lin X, Johnston D: Seizure-induced plasticity of h channels in entorhinal cortical layer III pyramidal neurons. Neuron 2004, 44:495–508.

37. Powell KL, Ng C, O'Brien TJ, Xu SH, Williams DA, et al: Decreases in HCN mRNA expression in the hippocampus after kindling and status epilepticus in adult rats. Epilepsia 2008, 49:1686–1695.

38. Bender RA, Soleymani SV, Brewster AL, Nguyen ST, Beck H, et al: Enhanced expression of a specific hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN) in surviving dentate gyrus granule cells of human and experimental epileptic hippocampus. J Neurosci 2003, 23:6826–6836.

39. Brewster A, Bender RA, Chen Y, Dube C, Eghbal Ahmadi M, Baram TZ: Developmental febrile seizures modulate hippocampal gene expression of hyperpolarization-activated channels in an isoform- and cell-specific manner. J Neurosci 2002, 22:4591–4599.

40. Dugladze T, Vida I, Tort AB, Gross A, Othahal J, et al: Impaired hippocampal rhythmogenesis in a mouse model of mesial temporal lobe epilepsy. Proc Natl Acad Sci USA 2007, 104:17530–17535.

41. Jung S, Jones TD, Lugo JN Jr, Sheerin AH, Miller JW, et al: Progressive dendritic HCN channelopathy in pilocarpine model of epilepsy. J Neurosci 2007, 27:13012–13021.

42. Shin M, Brager D, Jaramillo TC, Johnston D, Chetkovich DM: Mislocalization of h channel subunits underlies h channelopathy in temporal lobe epilepsy. Neuron 2008, 52:26–36.

43. Marcelin B, Chausiere L, Becker A, Migliore M, Esclapez M, Bernard C: h channel-dependent deficit of theta oscillation resonance and phase shift in temporal lobe epilepsy. Neurobiol Dis 2009, 33:436–447.

44. Nie Z, Hirsch DS, Randazzo PA: Arf and its many interactors. Curr Opin Cell Biol 2003, 15:396–404.

45. Teber I, Nagano F, Kremerskothen J, Bilbis K, Goud B, Barkenkov A: Rab6 interacts with the mint3 adaptor protein. Biol Chem 2005, 386:671–677.

46. Araki Y, Tomita S, Yamaguchi H, Miyagi N, Sumioka A, et al: Novel cadherin-related membrane proteins, Alcadine, enhances the X11-like protein-mediated stabilization of amyloid beta-protein precursor metabolism. J Biol Chem 2003, 278:49448–49458.

47. Araki Y, Kawano T, Taru H, Saito Y, Wada S, et al: The novel cargo Alcadine induces vesicle association of kinesin-1 motor components and activates axonal transport. EMBO J 2007, 26:1475–1486.

48. Kakuda N, Shoji M, Aral A, Furukawa K, Ikeuchi T, et al: Altered γ-secretase activity in mild cognitive impairment and Alzheimer's disease. EMBO Mol Med 2012, 4:344–352.

49. Ishii TM, Takano M, Chmori H: Determinants of activation kinetics in mammalian hyperpolarization-activated cation channels. J Physiol 2001, 537:599–100.

50. Zhu G, Okada M, Yoshida S, Ueno S, Mori F, et al: Rats harboring S284L Chmna4 mutation show attenuation of synaptic and extrasynaptic GABAergic transmission and exhibit the nocturnal frontal lobe epilepsy phenotype. J Neurosci 2008, 28:12465–12376.

51. Dickson CT, Magistretti J, Shalinsky MH, Fransen E, Hasselmo ME, Alonso A: Properties and role of I(h) in the pacing of subthreshold oscillations in entorhinal cortex layer II neurons. J Neurophysiol 2000, 83:2562–2579.

Cite this article as: Saito et al. Hyperpolarization-activated cyclic nucleotide gated channels: a potential molecular link between epileptic seizures and Aβ generation in Alzheimer's disease. Molecular Neurodegeneration 2012:50.